Cargando…

The aryl hydrocarbon receptor in tumor immunity

The aryl hydrocarbon receptor (AHR) binds environmental toxins and mediates immune regulation. The tryptophan metabolite kynurenine has now been identified as an endogenous ligand of the human AHR constitutively produced by gliomas and other types of cancer via tryptophan-2,3-dioxygenase (TDO), ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Platten, Michael, Litzenburger, Ulrike, Wick, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382870/ https://www.ncbi.nlm.nih.gov/pubmed/22737628 http://dx.doi.org/10.4161/onci.19071

Ejemplares similares

The Aryl Hydrocarbon Receptor and Tumor Immunity
por: Xue, Ping, et al.
Publicado: (2018)

Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D
por: Heinemann, Anja, et al.
Publicado: (2012)

The ART of tumor immune escape
por: Wennerberg, Erik, et al.
Publicado: (2022)

Author Correction: The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis
por: Lozza, Laura, et al.
Publicado: (2020)

Tumor-targeting vaccination instructs graft-vs.-tumor immune responses
por: Manzo, Teresa, et al.
Publicado: (2013)

Radiotherapy supports protective tumor-specific immunity
por: Gupta, Anurag, et al.
Publicado: (2012)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Host CD73 impairs anti-tumor immunity
por: Salmi, Marko, et al.
Publicado: (2012)

A novel role for granzymes in anti-tumor immunity
por: Hoves, Sabine, et al.
Publicado: (2012)

Egfl7 promotes tumor escape from immunity
por: Pinte, Sébastien, et al.
Publicado: (2012)

"Flagellated" cancer cells propel anti-tumor immunity
por: Garaude, Johan, et al.
Publicado: (2012)

Tumor suppressor ARF: The new player of innate immunity
por: Través, Paqui G., et al.
Publicado: (2012)

Antigen shedding into the circulation contributes to tumor immune escape
por: Höchst, Bastian, et al.
Publicado: (2012)

The immune landscape of human tumors: Implications for cancer immunotherapy
por: Bindea, Gabriela, et al.
Publicado: (2014)

Tumor spread or siege immunity: dissemination to distant metastasis or not
por: Bindea, Gabriela, et al.
Publicado: (2021)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

The role of SMAC mimetics in regulation of tumor cell death and immunity
por: Emeagi, Perpetua U., et al.
Publicado: (2012)

Synchronous apoptosis in established tumors leads to the induction of adaptive immunity
por: Honeychurch, Jamie, et al.
Publicado: (2013)

IL-33/ST2 axis in innate and acquired immunity to tumors
por: Jovanovic, Ivan P., et al.
Publicado: (2012)

Distinct anti-tumoral functions of adaptive immune cells in liver cancer
por: Schneider, Carlo, et al.
Publicado: (2012)

Emerging evidence of anti-tumor immune control in the central nervous system
por: Donson, Andrew M., et al.
Publicado: (2012)

How the devil facial tumor disease escapes host immune responses
por: Siddle, Hannah V, et al.
Publicado: (2013)

Is tumor (R)ejection by the immune system the “5th R” of radiobiology?
por: Golden, Encouse B, et al.
Publicado: (2014)

Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond
por: Urbanska, Katarzyna, et al.
Publicado: (2012)

Extending the chimeric receptor-based T-cell targeting strategy to solid tumors
por: Rossig, Claudia
Publicado: (2013)

Immune-mediated tumor evolution: Nanog links the emergence of a stem like cancer cell state and immune evasion
por: Mao, Chih-Ping, et al.
Publicado: (2014)

Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment
por: Jinushi, Masahisa
Publicado: (2012)

Alerting the immune system via stromal cells is central to the prevention of tumor growth
por: Issazadeh-Navikas, Shohreh
Publicado: (2013)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
por: Chew, Valerie, et al.
Publicado: (2013)

Chronic activation of DNA damage signals causes tumor immune evasion in the chemoresistant niche
por: Jinushi, Masahisa
Publicado: (2012)

In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence
por: Veenstra, Jesse J, et al.
Publicado: (2015)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors
por: Bellone, Matteo, et al.
Publicado: (2013)

Androgen receptor, ccl2, and epithelial-mesenchymal transition: A dangerous affair in the tumor microenvironment
por: Lin, Wen-Jye, et al.
Publicado: (2014)

Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles
por: Cubillos-Ruiz, Juan R., et al.
Publicado: (2012)

Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells
por: Beug, Shawn T, et al.
Publicado: (2014)

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
por: Smyth, Mark J, et al.
Publicado: (2014)

Bone marrow provides an environment that prevents suppression of therapeutic graft-vs.-tumor immunity by regulatory T cells
por: Guichelaar, Teun, et al.
Publicado: (2013)

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
por: Wainwright, Derek A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kdeh34jq1t29vpo3e5n02ht47j